Helicobacter pylori infection
Conditions
Interventions
14-day minocycline and vonoprazan dual therapy:14-day minocycline and vonoprazan dual therapy
14-day bismuth-containing quadruple therapy:14-day bismuth-containing quadruple therapy
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Individuals who have not undergone prior Hp eradication therapy; 2. Confirmed positive Hp infection via 13C-UBT (limited to Hidewei or 75mg Huagen breath test kits; a breath value >6 is considered positive; patients with breath values within the borderline range are excluded from enrollment); 3. Voluntary participation and signed informed consent. 4. Age range of 18-70 years old, gender not limited.
Exclusion criteria
Exclusion criteria: 1. Previous H. pylori eradication therapy; 2. Severe allergic constitution or allergy to this study drugs; 3. Zollinger-Ellison syndrome, hyperchlorhydria, or history of hyperchlorhydria; 4. Current acute upper gastrointestinal bleeding, presence of more than two peptic ulcers, or ulcers exceeding 0.5 cm in diameter; 5. History of gastric or intestinal resection affecting drug metabolism; 6. Concurrent severe systemic diseases (e.g., cardiovascular, respiratory, gastrointestinal, neurological), malignancy, or severe psychological/psychiatric disorders; 7. Concurrent severe hepatic or renal impairment (ALT and AST <= 1.5 times upper limit of normal; Cr <= upper limit of normal); 8. Use of PPIs or antibiotics within one month prior to screening; 9. Pregnant or lactating women; 10. Participation in other drug or medical device clinical studies within 30 days prior to screening; 11. Other factors deemed by the investigator to make the subject unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate of Hp infection; | — |
Secondary
| Measure | Time frame |
|---|---|
| The Outcome of the Gut Microbiome;Incidence of adverse events;Patient compliance;Hp antibiotic resistance rate; | — |
Countries
China
Contacts
Public ContactYin Zhu
The First Affiliated Hospital of Nanchang University
Outcome results
None listed